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Running Title: Clonal Responses in IDH2 mutant AML 34 
Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several 35 
types of cancer, including acute myeloid leukemia (AML). In model systems, mutant 36 
IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-37 
molecule inhibitor of mutant IDH2, produces a clinical response in 40% of treated 38 
relapsed/ refractory AML patients by promoting leukemic cell differentiation. Here, we 39 
studied the clonal basis of response and acquired resistance to enasidenib treatment. 40 
Using sequential patient samples, we determined the clonal structure of 41 
hematopoietic cell populations at different stages of differentiation. Pre-therapy IDH2 42 
mutant clones showed variable differentiation arrest. Enasidenib treatment promoted 43 
hematopoietic differentiation from either terminal or ancestral mutant clones; less 44 
frequently, treatment promoted differentiation of non-mutant cells. Analysis of paired 45 
diagnosis/relapse samples did not identify second site mutations in IDH2 at relapse. 46 
Instead, relapse arose by clonal evolution, or selection, of terminal or ancestral 47 
clones, highlighting multiple bypass pathways that could potentially be targeted to 48 
restore differentiation arrest. Mapping clonal structure in cell populations at different 49 
stages of differentiation during therapy illustrates how different clones respond and 50 
evolve during relapse.  51 
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Differentiation arrest is a common feature of many cancer cells. Though intratumoral clonal 52 
heterogeneity is well documented, we lack a detailed understanding of how the complement 53 
of driver mutations within a clone, contribute to differentiation arrest. Furthermore, though it 54 
is clear that genetic and functional, intratumoral heterogeneity helps determine clinical 55 
outcome to cancer therapy1,2, few studies have investigated the relationship between clonal 56 
structure and therapy response, particularly for therapies targeting oncogenic epigenetic 57 
processes. With an average of 13 somatic mutations per patient, arranged in an limited 58 
number of clones3, AML is simpler than most cancers from a genomic context, providing a 59 
potential paradigm to answer these questions.  60 
Somatic mutations in conserved arginine residues R140 and R172 in ISOCITRATE 61 
DEHYDROGENASE 2 (IDH2) occur in 15-25% of AML patients4-6. The mutant proteins have 62 
neomorphic activity producing R-2-hydroxyglutarate (2-HG) that competitively inhibits α-63 
ketoglutarate-dependent enzymes including the TET family of 5-methylcytosine (5mC) 64 
hydroxylases and Jumonji-C domain histone demethylases7,8. This leads to DNA 65 
hypermethylation9, increased repressive histone methylation8 and impaired hematopoietic 66 
differentiation that is reversed by mutant IDH inhibition in model systems 8,10-12. 67 
We recently showed that enasidenib (AG-221/CC-90007), a first-in-class, allosteric inhibitor 68 
of mutant IDH2 (mIDH2)13, reduces serum 2-HG, reverses DNA hypermethylation and 69 
promotes hematopoietic differentiation in preclinical models13,14. In a phase 1/2 clinical trial, 70 
enasidenib monotherapy produced a response rate of 40.3% in relapsed/refractory AML 71 
patients15. In most responding patients terminally mature blood cells were IDH2 mutant, 72 
consistent with response due to enasidenib-induced differentiation of IDH2 mutant cells16. 73 
However, in 9/71 (12.6%) responding patients, IDH2 mutant cells were eliminated from 74 
peripheral blood cells16. Failure to respond to enasidenib was associated with a higher co-75 
mutational burden and NRAS mutations16. Finally, most patients who initially responded 76 
eventually relapsed. These initial studies did not assess which clone(s) differentiated in 77 
response to enasidenib and the clonal mechanism of acquired enasidenib resistance.  78 
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We have addressed these two questions by studying sequential samples from a subset of 79 
trial patients. We showed marked variation in the degree of differentiation arrest of mutant 80 
IDH2 clones. Restoration of differentiation by inhibition of mutant IDH2 was also clone 81 
dependent, varying between patients, arising from either ancestral or terminal clones. In a 82 
minority of patients differentiation occurred from wild type progenitor cells, consistent with 83 
molecular remission in a subset of patient. Acquired resistance to enasidenib leading to 84 
differentiation arrest and relapse did not occur by second site mutations in IDH2. Instead, 85 
differentiation arrest was restored by multiple mechanisms through clonal evolution or clonal 86 
selection. 87 
Results 88 
Patient cohort studied 89 
The trial enrolled 176 relapsed/refractory IDH2 mutant AML patients15. Here, we studied a 90 
cytogenetically and genetically representative subset of 37 patients enriched for enasidenib 91 
responders (30/37 responders, Supplementary Fig. 1a-c). An extended mutational profile 92 
was determined in 33/37 patients by either whole exome sequencing (WES) (16/36 patients 93 
at read depth of 19-843x, average 121x at loci where variants were called), or targeted 94 
resequencing (17/36 patients) (Supplementary Tables 1 and 2). Compared to the entire 95 
trial cohort, the patient cohort studied here had similar serum baseline 2-HG levels and the 96 
mean level of 2-HG suppression was similar in the two cohorts (i.e. on-target response to 97 
enasidenib; Supplementary Fig. 1d-e).  98 
Enasidenib rebalanced progenitor and precursor compartment sizes and restored 99 
progenitor function 100 
In AML there are two orthogonal potential hierarchies (Supplementary Fig. 2a). There is 101 
clonal hierarchy with an initiating clone, transitional and terminal clones. We refer to all non-102 
terminal clones as ancestral clones. These mutant clones exist in a second hierarchy, a 103 
hematopoietic cell hierarchy. AML initiating mutations occur in stem, or long-lived progenitor, 104 
cells but initiating clones are not usually arrested in differentiation17-19. However, with 105 
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acquisition of additional, transforming mutations and epigenetic alterations, clones fail to 106 
complete maturation. In the fully transformed state, haemopoiesis in human AML is 107 
dominated by expansion either of progenitor-like cells, presumably because of a 108 
differentiation block between progenitor and downstream precursor cells20, or less 109 
commonly, by precursor-like cells, presumably because of a differentiation block between 110 
precursor and mature cells21. In both cases, expanded leukemic progenitor-like, or 111 
precursor-like, populations have functional leukemic stem cell activity20,21. Thus, we set out 112 
to address three questions: (i) where are individual clones arrested in the hematopoietic 113 
hierarchy; (ii) which clone(s) responded to mutant IDH2 inhibition by differentiating; (iii) which 114 
clone(s) were responsible for loss of response to enasidenib, after an initial response, and 115 
by what mechanism? 116 
The experimental approach is set out in Supplementary Fig. 2b. We first performed flow 117 
cytometric quantitation of hematopoietic stem/progenitor (Lin-CD34+CD117+), precursor (Lin-118 
CD34-CD117+) and mature myeloid cell (Lin-CD34-CD117-) populations21 at trial entry in 15 119 
patients (Fig. 1a-b and Supplementary Fig. 3a-b). Sizes of individual stem/progenitor 120 
populations within Lin-CD34+ cells were also quantitated. 11/15 patients had abnormally 121 
expanded progenitor-like compartments (mainly LMPP-like and GMP-like; termed progenitor 122 
AML) and 4/15 abnormally large myeloid precursor-like populations (termed precursor AML). 123 
The ratio of progenitor: precursor AML is consistent with previous studies20,21.  124 
Next, we analysed the bone marrow (BM) stem/progenitor/precursor populations in 5 125 
patients who achieved complete remission (CR) with enasidenib (Fig. 1b-c). In all 5 there 126 
was near normalization of the sizes of the stem/progenitor compartments. Pre-treatment, 2 127 
patients had pathologically expanded LMPP- and GMP-like progenitor populations (#201-128 
023, #201-011) and 2 patients had expanded myeloid precursor compartments (#201-010 129 
and #203-002). Functionally, Lin-CD34+ progenitor cells from these 5 patients in CR formed 130 
myeloid/ erythroid colonies nearly as efficiently as normal cells, in contrast to cells from 131 
patients who did not achieve CR (Fig. 1d)(Supplementary Fig. 3c-d). Thus, enasidenib 132 
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therapy rebalanced the sizes of hematopoietic stem/progenitor/precursor/mature populations 133 
at CR with reacquisition of normal myeloid progenitor function. 134 
Wild type hemopoiesis occurs occasionally with enasidenib therapy 135 
Next, we investigated the clonal basis of differentiation. In principle, enasidenib could have, 136 
directly or indirectly, restored differentiation from either wild type cells, ancestral clones or 137 
terminal clones in a clonal hierarchy (Fig. 2a). We established the clonal basis of response 138 
in 6 patients using samples taken at multiple time points before and through treatment, 139 
including relapse (Fig. 2b). We used WES and karyotype of bone marrow mononuclear cells 140 
(BMMNCs) to determine chromosomal copy number and mutational changes 141 
(Supplementary Tables 2-3). Next, we used WES data to design patient-specific mutation 142 
panels to test variant allele frequencies (VAFs) of mutations in unsorted BMMNCs and flow-143 
cytometric sorted hematopoietic stem/progenitor/precursor/mature cell populations and 144 
genotype flow-cytometric sorted single cells and hematopoietic colonies derived from single 145 
cells (Supplementary Table 3). A combination of all these data was used to establish clonal 146 
structures. Details on setting false positive and negative thresholds in single cell genotyping 147 
(SCG) are presented in Methods.  148 
In our initial study, 9 out of 29 patients who achieved CR, for whom samples were available, 149 
had loss of mutant IDH2 peripheral blood cells (complete molecular remission in peripheral 150 
blood16. However, it was unclear if these differentiated blood cells were truly wild type, or 151 
from a genetically mutant clone(s) that just lacked mutant IDH2? We studied this question in 152 
a patient with mutations in IDH2 (I), PEX26 (P), FEZ2 S208T (F), DNMT3B (D), ZCCHC1 153 
(Z), NPM1 (N), and ELMO3 (E) in AML blasts pre-enasidenib (#201-022, Fig. 2c) who 154 
achieved mutant IDH2 molecular remission. Pre-therapy, imputation from variant allele 155 
frequency (VAF) suggested presence of wildtype cells and three possible mutant clones: a 156 
clone with IDH2 mutation alone (I), a clone with genotype IPFDZN and a minor clone that 157 
was either IPFDZNE or IE (Supplementary Fig. 4a-c), though the exact clonal structure 158 
could not established unambiguously (Supplementary Fig. 4d-h). At CR, the VAF of all 159 
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mutations was <1.6% (Fig. 2c, Supplementary Table 4 for depth of sequencing). 160 
Concordantly, at CR the majority (94.6%) of 111 individually genotyped hematopoietic 161 
colonies did not contain any mutations present pre-therapy (Fig. 2d). Functionally, the 162 
colonies produced a normal ratio of myeloid to erythroid colonies consistent with a wild-type 163 
genotype (Fig. 2e). Thus, in a minority of patients, enasidenib therapy resulted in restoration 164 
of wild type terminal blood cell production and progenitor function from wild-type cells. 165 
Enasidenib restored differentiation from ancestral and terminal clones in a clone 166 
dependent manner 167 
In one patient enasidenib promoted differentiation from an ancestral clone (#201-023, Fig. 168 
3). WES and targeted resequencing of BMMNCs pre-enasidenib detected mutations in 169 
SRSF2 (S), IDH2 (I), ASXL1 (A), GATA2 (G) and two mutations in RUNX1 (R, r) 170 
(Supplementary Tables 2-3). Pre-therapy imputation of clonal structure based on VAF in 171 
unsorted BMMNCs by exome and targeted resequencing suggested initial acquisition of 172 
SRSF2 mutation (clone S) followed by an IDH2 mutation (clone SI) followed by acquisition of 173 
ASXL1 (A), the two RUNX1 and GATA2 mutations (Supplementary Fig. 5a and 174 
Supplementary Tables 2-3). At CR, only mutations SRSF2 (S), IDH2 (I), ASXL1 (A) were 175 
detected in mature cells supporting the existence of an SIA clone that preferentially 176 
completes terminal maturation in presence of enasidenib (Supplementary Fig. 5a-c).  177 
To clarify clonal structure, and position clones within the haemopoietic hierarchy, we 178 
performed targeted resequencing for driver variants in 63 single cells and cell populations, 179 
from flow-cytometric sorted progenitor and mature myeloid cell compartments, from both 180 
pre-therapy and CR samples (Fig. 3a-b and Supplementary Table 3). This confirmed a 181 
linear clonal evolution pattern: clone SI preceded clone SIA, followed by clones that 182 
sequential acquired RUNX1 mutations (clones SIAR and SIARr) and finally the terminal 183 
clone acquired a GATA2 mutation (SIARrG). The mutational profile in 4 single cells did not fit 184 
into this clonal evolution pathway. We detected a single cell with an ASXL1 mutation (clone 185 
A) and three single cells with both ASXL1 and SRSF2 mutations (clone AS). In three cells 186 
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with genotype AS, we detected allele dropout (ADO) of the IDH2 allele in two out of three 187 
cells. Thus, we are unable to determine the mutational state of IDH2 in those two cells. In 188 
contrast, in twelve cells of the SI clone, ADO of the ASXL1 allele was detected in only three 189 
out of twelve cells (Supplemental Fig. 12a). Thus, though our results do not exclude a rarer, 190 
parallel clonal evolution pathway where clones A and AS exist and failed to acquire 191 
mutations in the order shown in the main pathway, they also are consistent with these cells 192 
being part of the main clonal evolution pathway.  193 
Pre-therapy, 90% of BMMNCs were progenitors (LMPP and GMP) (Fig. 1c and 3d) and 90-194 
100% of these leukemic progenitors were the SIARrG clone (Fig 3c). Thus, the SIARrG 195 
clone is arrested in differentiation at the progenitor stage and expands to dominate the 196 
marrow. Less than 10% of BMMNCs were mature myeloid cells (Fig 1c and Fig 3d). We 197 
were only able to genotype 8 mature myeloid cells pre-therapy (Fig. 3c) and they are 198 
composed of a mixture of wild type cells and of cells with genotypes A, SI, AS and SIA. At 199 
CR, the mature myeloid cell compartment comprised 60% of BMMNCs (Fig 1c and Fig 3d) 200 
and 85% of mature cells have the SIA genotype (Fig. 3d and Supplementary Fig. 5b, 201 
Supplementary Table 3).  202 
The progenitor compartment was only 20% of BMMNCs at CR (Fig. 1c and Fig 3d) and 203 
composed of mixed ancestral clones SI, SIA, SIAR but not the terminal clone SIARrG. 204 
Concordantly, the majority of colonies generated by progenitors at CR were “SIA”, with a 205 
minority of the SI and SIA genotype (Fig. 3e). The ratio of myeloid:erythroid colonies was 206 
within normal limits (Fig. 3f) Taken together, this data demonstrated a complex, clone-207 
dependent pattern of enasidenib-induced differentiation with mature myeloid cell production 208 
sustained principally by a self-renewing ancestral SIA clone.  209 
In four patients, differentiation of mature cells was principally seen from terminal clones (Fig. 210 
2b). In patient #201-011, WES (Supplementary Table 2) and targeted resequencing of 211 
BMMNC revealed two mutations in DNMT3A and mutations in IDH2, ASXL1 and XPO1 pre-212 
therapy that persisted at different VAFs at CR (Supplementary Table 3, Supplementary 213 
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Fig. 6a). However, it was not possible to impute the clonal structure from the VAF 214 
(Supplementary Fig. 6b). We genotyped 110 single cells, pre-therapy and at CR (Fig. 4a). 215 
This revealed an initiating DNMT3A clone (clone D) that acquired an IDH2 mutation (clone 216 
DI) (Fig. 4b). Subsequently, there is a branching clonal structure with two terminal clones; 217 
one acquired an XPO1 mutation (clone DIX), whereas the other acquired two mutations, a 218 
second DNMT3A mutation and an ASXL1 mutation (clone DIdA). SCG suggested the DIdA 219 
clone may have arisen by convergent evolution through intermediate DId and DIA clones. 220 
There is a caveat with this interpretation as ADO was detected in 6 out of 7 DIA clone cells 221 
(Supplemental Fig. 12d). In the DId cells, though there were no heterozygous germline 222 
single nucleotide polymorphisms in the ASXL1 gene, the estimated ADO frequency of the 223 
ASXL1 allele was 12.1% (Supplemental Fig. 12e). Thus, it is also possible that the DIdA 224 
clone may also have arisen through just one mutational pathway. 225 
Pre-enasidenib, 89% of BMMNCs were leukemic progenitors (LMPP and GMP) virtually 226 
exclusively composed of the DIX clone (Fig. 4c-d). A small mature myeloid population is 227 
present pre-enasidenib composed of the DIdA clone (Supplementary Fig. 6c). These 228 
observations suggest that the IDH2 mutation in the context of the DIdA clone is not fully 229 
effective at imposing a complete differentiation block, whereas the same IDH2 mutation in 230 
the context of the DIX clone fully arrests at a progenitor stage.  231 
At CR, 82% of BMMNCs were composed of mature myeloid cells, 85% of which were a mix 232 
of two terminal branching clones DIdA (54%) and DIX (31%) suggesting enasidenib 233 
promoted differentiation from both terminal clones (Fig. 4c-d, Supplementary Table 3). To 234 
address which progenitors contribute to mature cell output we genotyped single flow 235 
cytometric sorted progenitors. The DIdA clone dominated mature GMP, CMP and MEP 236 
progenitor compartments (Fig. 4c-d). In contrast, clone DIX was detected only in the more 237 
immature LMPP progenitor compartment. GMP, CMP and MEP are more clonogenic than 238 
the LMPP20,22 and concordantly, ~95% of colonies had the DIdA genotype (Fig. 4e) that 239 
were myeloid-biased (Fig. 4f). Interestingly, there is a substantial decrease in the size of the 240 
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LMPP compartment at CR compared to pre-therapy (Fig. 4d) (1240-fold decrease within the 241 
Lin- compartment and 81-fold within the CD34+ compartment).  242 
In three additional patients the terminal clone contributed to mature myeloid cells at CR 243 
based on imputed clonal structures, genetic analysis of mature myeloid cells at CR (patient 244 
#201-010, Supplementary Fig. 6d-e) and genotyping of myeloid colonies at CR (patient 245 
#201-027, Supplementary Fig. 7a-d; patient #201-006 Supplementary Fig. 7e-h). Depth of 246 
coverage for each of the mutations in all three patients is in Supplementary Table 4. 247 
In summary, enasidenib therapy provides relief of differentiation arrest at a progenitor-like or 248 
precursor-like stage, normalizing the sizes of these abnormally expanded compartments. 249 
The ability of mutant IDH2 to impose differentiation block is dependent on the context of co-250 
associated mutations within a clone. Consequently, efficacy of enasidenib-induced 251 
differentiation is also is likely to dependent mutational landscape within a clone.  252 
Relapse of IDH2 mutant patients on enasidenib occurs by clonal selection/evolution 253 
and not second site mutations in IDH2 gene 254 
Although responding patients have a median survival of 18-21 months, many patients 255 
relapse15. To study mechanisms leading to relapse we measured 2-HG levels in 16 patients 256 
at diagnosis and relapse, mutational profiles in 12 patients (by WES in 11 cases and 257 
targeted sequencing in the other patient) and performed karyotype analysis in 11 subjects 258 
(Fig. 5a-b and Supplementary Table 5). We did not detect second site IDH2 mutations at 259 
relapse in any patient but instead documented 7 patterns of clonal evolution/selection with 260 
acquisition of recurrent AML-associated genetic changes (Fig. 5a). These are recurrent 261 
missense mutations in myeloid malignancy, or nonsense and frameshift mutations in 262 
cancers, as documented in the COSMIC database (http://cancer.sanger.ac.uk/cosmic). For 263 
patient #201-007, mutations were detected prior to relapse, but increased in frequency at 264 
relapse (Supplementary Table 3). 265 
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In 14/16 patients 2-HG levels remained suppressed between best response (CR or PR) and 266 
relapse suggesting drug was on target in suppressing neomorphic enzyme function (Fig. 267 
5b). However, in 2 patients (#201-014 and #201-022) rising 2-HG levels and BM leukemic 268 
cells (blasts) were seen (Fig. 5c-d). Exome sequencing revealed IDH1 R132C/H mutations 269 
albeit accompanied by other genetic abnormalities, some of which are recurrent in AML 270 
(point mutations in RUNX1, NPM1 and t(3:12)) (Fig. 5e-f). These IDH1 mutations were 271 
previously undetectable by high depth NGS (10000x) pre-enasidenib therapy. Surprisingly, 272 
in both cases, the VAF indicates that IDH1 mutations were present in IDH2 mutant clones.  273 
Relapse also associated with increasing VAF of oncogenic gain of function mutations in 274 
genes encoding cytokine receptors CSF3R (patient #104-021, Supplementary Fig. 8a-b) 275 
and FLT3 (patients #201-013, #201-004 Supplementary Fig. 8c-d and #201-007 276 
Supplementary Fig. 9f-h) and predicted loss of function mutation in the negative regulator 277 
of cytokine signalling CBL (#201-004 Supplementary Fig. 8d). For patient #104-021 we 278 
could not resolve the clonal structure from targeted resequencing of BMMNC 279 
(Supplementary Fig. 8b, Supplementary Table 2) but genotyping of 214 single cells pre-280 
enasidenib and at relapse (Fig. 6a) demonstrated an initiating DNMT3A/ IDH2 mutant clone 281 
that spawned the major clone with a recurrent U2AF1 mutation (DIU clone). A minor DIUF 282 
clone with a D200E variant in the FLT3 (not previously described in AML) was also present 283 
pre-enasidenib. At relapse, the major clone in the expanded arrested LMPP and GMP 284 
compartments had acquired an oncogenic T618I mutation in the cytokine receptor CSF3R 285 
that is well described in myeloid leukemias23 (DIUC clone). DIUC further evolved, acquiring a 286 
variant in NFKB1 that has not been described previously in AML. Mutations in both CSF3R 287 
and NFKB1 were detectable at threshold of sensitivity pre-enasidenib (Supplementary Fig. 288 
8a). 289 
Relapse, and re-imposition of differentiation block, was also associated with previously 290 
described mutations in hematopoietic transcription factors in myeloid cancers. These 291 
included frame shift mutations in RUNX1 (Fig. 5e and Supplementary Fig. 8e one of which 292 
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has been previously described in AML (RUNX1 F416fs) 24) and BCORL125; non-synonymous 293 
variants, in the DNA- and protein-partner binding N-terminal zinc finger of GATA2 294 
(Supplementary Fig. 8d)26,27 and in one of the zinc fingers of BCL11A28 (Supplementary 295 
Fig. 8c). In all patients these mutations were not detected pre-enasidenib. 296 
Deletion of all (monosomy 7), or part (del 7q) of chromosome 7 is common in myeloid 297 
malignancy29. Chromosomal abnormalities were present in 18% of the enasidenib cohort15 298 
and 20% in the cohort studied here (Supplementary Fig 1). Del 7q was detected in 4 out of 299 
12 patients who relapsed (#201-010, #201-007, #201-019 and #201-003) (Fig. 5a, 300 
Supplementary Table 5) but are not enriched in relapsed patients (Amatangelo, M., 301 
Thakurta, A., unpublished data). In all four patients it was detected either cytogenetically, or 302 
by WES, pre-enasidenib therapy (Supplementary Tables 2 and 5). In three out of the four 303 
cases the del 7q clone was selected at relapse (Supplementary Fig. 9a-e, k and l). In one 304 
case where it was not, it was the dominant clone pre-therapy and at relapse 305 
(Supplementary Fig. 9g-j). 306 
Clonal evolution at relapse also highlighted variants in genes less well studied in AML 307 
including NFKB1 M216I (Fig. 6a-d), DDX1 G699A (Supplementary Fig. 8c), MTUS1 308 
Q781H (Supplementary Fig. 9f-i), DHX15 R222G and DEAF1 N372K (Fig. 6e-h). Of these, 309 
acquisition of latter two variants by patient #201-011 at relapse is worthy of comment. Pre-310 
enasidenib the patient had expanded LMPP and GMP populations composed of an arrested 311 
DIX clone (Fig. 4b). At CR the DIX clone was able to differentiate but only persisted within 312 
the LMPP compartment (Fig. 4d). At relapse, we detected 30 cells with DIX mutations that 313 
acquired a missense mutation in the DExD/H-box helicase DHX15 R222G (mutation H), 7 314 
cells with the DIX mutations that had acquired a variant in the transcription factor DEAF1 315 
N372L (variant F) and 12 cells with the DIXHF variants (Fig. 6e-f). However in 6 out of 7 316 
DIXF cells there was ADO for the DHX15 allele with the DHX15 R222G mutation and 317 
therefore we are unable to determine whether the DHX15 R222G is present in those cells 318 
(Supplementary Fig. 12c). 319 
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Acquisition of the additional DHX15 and DEAF1 mutations was associated with 320 
differentiation arrest, and a re-expansion of LMPP and GMP progenitor compartments, 321 
comprising 89% of MNCs. 83% of LMPP cells were composed of the DIXH and DIXHF 322 
clones whereas in the GMP-like compartment there was a more even contribution by the 323 
DIXHF, DIXH and DIXF clones (Fig. 6g-h).  324 
Finally, both DHX15 and DDX1 regulate RNA splicing. Human DHX15 is structurally closely 325 
related to its yeast homologue, Prp4330,31. Both proteins have been shown to contribute to 326 
disassembly of splicesomes, efficient debranching and turnover of excised introns32,33. 327 
DHX15 R222G mutations have been previously described in AML34,35. To determine if 328 
acquisition of DHX15 R222G results in altered splicing we performed RNA-Seq of AML 329 
blasts at relapse from patient #201-011 and compared splicing to AML cells from the same 330 
patient that were wild type for DHX15 at trial entry (Supplementary Fig. 8f). In cells 331 
expressing DHX15 R222G, there were alterations in exon skipping and intron retention 332 
compared to cells wild type for DHX15. DDX1 is a DEAD-box RNA helicase with 5’ single 333 
stranded RNA exonuclease activity postulated to have multiple roles in RNA metabolism36. 334 
DDX1 G699A has not been previously described as a cancer-associated mutation nor has 335 
its impact on RNA splicing been studied. Our data shows an increase in intron retention and 336 
use of alternative 5’ and 3’ splice sites, and a decrease in spliced exons in mutant compared 337 
to wild type AML cells from the same patient (Supplementary Fig. 8g). 338 
Discussion 339 
This study of clonal response and acquired resistance in sequential paired samples from 340 
AML patients treated with an IDH2 inhibitor extends prior preclinical studies13,14. Pre-341 
enasidenib there were complex patient- and clone-specific patterns of differentiation arrest. 342 
At CR, wildtype dominated cellular reconstitution was less common but does occur. More 343 
commonly, enasidenib causes a clone-specific differentiation response, either from ancestral 344 
or terminal clones, leading to near normalization of the sizes and functionality of progenitor 345 
and precursor hematopoietic compartments with altered clonal mix. Acquired resistance was 346 
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never due to a second site mutation in the same IDH2 allele but instead due to either clonal 347 
evolution or clonal selection. At least 7 different mutational mechanisms led to re-imposition 348 
of differentiation arrest (Supplementary Fig.10). 349 
In most patients enasidenib was unable to promote terminal differentiation and eradication of 350 
IDH2 mutant clones; ancestral and/or terminal clones remained at CR. In patients with 351 
restitution of wild type hemopoiesis, we infer that enasidenib most likely promoted terminal 352 
differentiation of arrested self-renewing IDH2 mutant cells, allowing normal cells to dominate 353 
hemopoiesis. Longer term clinical follow up of molecular CR patients will determine if 354 
molecular CR patients have a better clinical outcome and if they relapse, the clonal origin of 355 
relapse. More generally, understanding the molecular mechanisms of relief from 356 
differentiation arrest by IDH2 inhibitors will require in depth study of changing patterns of 357 
epigenetic marks and transcriptional programmes within highly purified, clone-specific, 358 
hematopoietic stem, progenitor and precursor populations, before and after drug exposure, 359 
as transcriptional and epigenetic profiles are so highly plastic through differentiation.  360 
Drug resistance to targeted cancer therapy arises by multiple mechanisms. Resistance to 361 
kinase inhibitors in AML37,38, chronic myeloid leukemia39, chronic lymphoid leukemia40 and 362 
lung cancer41,42 often involves second site mutations in the mutant allele modulating drug or 363 
substrate binding or copy number changes of the mutant kinase. We did not observe this in 364 
enasidenib treated patients.  365 
Acquired resistance led to IDH2 could arise by either epigenetic or genetic mechanisms or a 366 
combination of the two. In most patients 2HG remained suppressed at relapse suggesting 367 
that enasidenib remained on target and relapsed clones were not dependent on mutant 368 
IDH2. In hematologic malignancies, genome-wide epigenetic variation (DNA methylation for 369 
example) can be several orders more variable than genetic change43-45, is somatically 370 
heritable, and subject to selection. Locus-specific DNA methylation (epiallele) variation 371 
shows dynamic change in AML between diagnosis and relapse and can occur with distinct 372 
kinetics, such that some patients have a high epiallele diversity and low somatic mutation 373 
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burden and vice versa45. In melanoma, resistance to a B-RAF inhibitor arose in rare cells 374 
through stochastic, transient variation in gene expression that was selected for by therapy46. 375 
This is consistent with prior work on chromatin mediated drug resistance in cancer cell 376 
lines47. 377 
Clones acquiring gene mutations, or grosser genetic changes, have previously been 378 
reported in therapy resistant chronic lymphocytic leukemia48 and medulloblastoma49. 379 
Acquisition of an IDH1 mutation in two patients is an example of how this may occur. Here, 380 
these AML propagation is likely to be highly dependent to high 2HG. 2HG addiction may be 381 
AML cell autonomous or alternatively, the 2HG requirement may be in BM niche supporting 382 
cells or other non-AML cell populations. AML clone-specific and non-AML cell specific 383 
analysis of the impact of 2HG on epigenetic and transcriptional programs and metabolism of 384 
cells50 is needed to understand this dependency. Other examples genetic changes leading 385 
to enasidenib resistance include gain of function mutations in proliferative cytokine signalling 386 
pathways and loss of or altered function in transcriptional regulators of hemopoiesis. 387 
However, mutations in the RAS pathway that are correlate with failure of initial response16 388 
were not associated with acquired resistance. 389 
We also detected variants at relapse not previously well studied in AML. An example of this 390 
is the DHX15 R222G mutation, recently described in RUNX1-RUNXT1 AML34. The yeast 391 
homologue of DHX15, Prp43, regulates RNA splicing and ribosome biogenesis. Loss of wild 392 
type DHX15 and overexpression of mutant DHX15 increases alternative splicing. In contrast, 393 
a role for DEAF1 has not been previously published in normal or malignant hemopoiesis. 394 
Curiously DEAF1 is a paralog of the transcription factor, RUNXT1. DEAF1 is expressed 395 
throughout hemopoiesis but particularly in GMP and AML blasts21. In non-hemopoetic 396 
tissues it binds to LMO4, a member of the LMO transcriptional adapter protein family. In 397 
blood cells, LMO2, a closely related LMO family member, partners transcription factors 398 
including GATA, E-box proteins and LDB1 to form regulatory and oncogenic protein 399 
complexes. Thus, the role of DEAF1 in hemopoiesis and its interaction with DHX15 merits 400 
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further study. More broadly, a deeper mechanistic understanding of how wild-type IDH2 401 
promote hematopoietic differentiation, which is currently poorly understood, will also 402 
increase our understanding of how bypass pathways could re-impose differentiation block, 403 
for example by altering transcriptional programmes, as seen in BET inhibitor therapy 404 
resistance51.  405 
Finally, this study demonstrates how any cancer therapy alters clonal structure across a fully 406 
transformed and pre-malignant cellular hierarchy. By defining clonal structures and mapping 407 
where clones were arrested across differentiation, in purified hematopoietic compartments, 408 
we obtained a previously unavailable view of where different clones were arrested. This 409 
provides the necessary information to study why clones are arrested at different stages of 410 
differentiation. Furthermore, analysis of sequential samples through therapy shows how 411 
clones differentially responded to therapy. This provides the basis to study clone specific 412 
relief of IDH2 inhibition. More generally, our approach could be applied to any cancer 413 
therapy, where single cell suspensions and purification of cells at different stages of 414 
differentiation is possible. This would then provide a clone specific understanding of how 415 
therapy alters clonal structure through a cellular hierarchy. Our approach also provides 416 
insights towards a rational basis for combination therapies to reduce drug resistance.  417 
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Figure Legends 573 
Figure 1. Enasidenib treatment induces differentiation of AML progenitor and 574 
precursor cell populations and restores progenitor function. 575 
a) Top, immunophenotyping of hematopoietic stem/progenitor/precursor and mature cell 576 
populations in AML bone marrow (BM) samples pre-treatment showing expanded progenitor 577 
(n=11 biologically independent samples) or precursor (n=4 biologically independent 578 
samples) populations with normal BM (n=8 biologically independent samples). Below, 579 
detailed composition of stem/progenitor compartments in AML pre-treatment (n=15 580 
biologically independent samples) and normal BM (n=12 biologically independent samples). 581 
Error bars in normal BM= 95% confidence interval. HSC: hematopoietic stem cell, MPP: 582 
multipotent progenitor, LMPP: lymphoid-primed multipotent progenitor, CMP: common 583 
myeloid progenitor, MEP; megakaryocyte-erythroid progenitor; GMP: granulocyte-584 
macrophage progenitor.  585 
b) Top, schematic representation of flow cytometric approach and sequential gates used to 586 
analyse samples in (a). Lin-, lineage negative; BMMC, bone marrow mononuclear cells. 587 
Bottom, example of flow plots from a representative sample prior to enasidenib treatment 588 
(Pre-ENA) and at complete remission (CR) in patients with expanded progenitor-like 589 
populations (#201-023; left, experiment performed once) or expanded myeloid precursor-like 590 
population (#201-010; right, experiment performed once). Numbers shown within the gate 591 
indicate percentage of the corresponding cell population compared to all cells in the plot.  592 
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c) Top, immunophenotyping of hematopoietic cell populations in normal BM (left, as in (a)) 593 
and in samples from 5 patients (#201-023, #201-011, #201-022, #201-010, #203-002) pre-594 
ENA, at intermediate time points during treatment, and at CR. Bottom, sizes of stem and 595 
progenitor compartments. Abbreviations and error bars in normal BM are as in (a). C=cycle, 596 
D=day.  597 
d) Number of mixed erythroid-myeloid colonies (GEM), granulocyte-macrophage (GM), 598 
granulocyte (G), macrophage (M) and erythroid (E) colonies produced per 100 plated flow-599 
sorted CD34+ cells from normal BM (n=4 biologically independent samples), enasidenib-600 
treated patients in CR (n=5 biologically independent samples) and enasidenib-treated 601 
patients not in CR (n=3 biologically independent samples). Patient samples were plated with 602 
addition of Enasidenib (1µM) to semi-solid media. Error bars= standard error of the mean. P-603 
values determined by 2-sided Student’s paired t-test.  604 
Figure 2. Differentiation response arising from wild-type cells in patients treated with 605 
enasidenib. 606 
a) Schematic representation of varying possible clonal responses to enasidenib. Four 607 
mutations (A, B, C and D) are present in four clones that are arranged in a branching 608 
structure. A differentiation response to enasidenib treatment could potentially occur from 609 
either wild type cells or from ancestral or terminal clones.  610 
b) Summary of the type of differentiation response (from either wild type cells, ancestral or 611 
terminal clones) in samples from 6 patients.  612 
c) Variant allele frequencies (VAF) of the indicated mutations in AML blasts of patient #201-613 
022 prior to enasidenib treatment (Pre-ENA) and in peripheral blood mononuclear cells 614 
(PMNC) at CR, as assessed by targeted re-sequencing. 615 
d) Clonal contribution to colony output from the CR sample from patient #201-022, as a 616 
percentage of all individually picked colonies genotyped. Clones were identified as wild type 617 
(WT), carrying the FEZ2 P118S mutation (F), or carrying the FEZ2 P118S and DNMT3B 618 
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N738S mutations (FD).  Lineage affiliations of the colonies are as in Fig. 1d. Numbers next 619 
to the bars indicate the number of colonies analyzed.  620 
e) Bar graph showing the lineage affiliation of colonies from Lin-CD34+ normal cord blood 621 
(CB) cells (n=5 biologically independent samples) and CD34+ BM cells in the CR sample of 622 
patient #201-022. Numbers next to the bar indicate the number of colonies produced per 100 623 
plated cells. The GM:E (granulocyte-macrophage:erythroid) ratio of colonies and the 95% 624 
confidence interval for the GM:E ratio in normal BM are shown.  625 
Figure 3. Enasidenib induces differentiation from an ancestral IDH2 mutant clone. 626 
All data shown refer to samples from patient #201-023. 627 
a) Heat map of targeted re-sequencing of mutations (rows) in single cells (columns, n=63 628 
cells) from flow-sorted BM populations isolated pre-ENA and at CR which are shown 629 
together.  Clonal identification of each cell is shown below the heat map and the key to 630 
mutations is denoted by letters on the right. Mutation detection key: red=detected; blue=not 631 
detected; white= sequencing failed.  632 
b) Clonal structure of the AML sample based on single cell genotyping (SCG). Number next 633 
to a clone indicates the number of cells identified in that clone (data from a). The most likely 634 
clonal structure is shown in solid arrows with alternatives in dotted arrows. (*) indicates 635 
genotype “A” or “SIAR”, which were each detected in only 1 cell. § indicates genotype “AS” 636 
with ADO of an IDH2 allele in 2/3 cells. Ø “SI” with ADO of the ASXL1 allele in 3/12 cells. 637 
See also Supplementary Fig. 12a. 638 
c) Clonal composition in different immunophenotypic compartments pre-ENA and at CR. 639 
Number of cells studied are indicated. 640 
d) Clonal contribution (vertical bars) to immunophenotypic stem, progenitor, myeloid 641 
precursor and terminal mature GM populations in patient samples pre-ENA and at CR 642 
(horizontal bars).  Data is from SCG except for mature GM population at CR, where the flow-643 
sorted cell population was genotyped (*).  Normal BM is shown for comparison of 644 
immunophenotypic populations.   645 
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e) Clonal contribution to colonies grown from CR sample (percentage of genotyped, 646 
individually picked colonies). Key to mutations detected are as in (b). Numbers next to the 647 
bars indicate the numbers of colonies analyzed. Lineage affiliations are as in Fig. 1d. 648 
f) Lineage affiliation of colonies from BM CD34+ cells purified from CR sample compared 649 
with normal CB (as in Fig. 2e).  650 
Figure 4. Enasidenib induces differentiation from a terminal IDH2m clone. 651 
All the data here are from patient #201-011. 652 
a) Heat map of targeted re-sequencing of mutations (rows) in single cells (columns, n=110 653 
cells) from flow-sorted BM populations pre-treatment and CR which are shown together. The 654 
key is as in Fig. 3a.  655 
b) Clonal structure of the AML sample based on SCG. The key to the panel is as in Fig. 3b. 656 
* marks the genotype “DIA” where ADO was detected in 6/7 cells. Ø denotes genotype “DId”. 657 
No heterozygous germline SNPs were available in the ASXL1 gene. Estimated ADO 658 
frequency of the ASXL1 allele was 12.1%. See also Supplementary Fig. 12c. 659 
c) Clonal composition in different immunophenotypic compartments pre-ENA and at CR, as 660 
in Fig. 3c. 661 
d) Clonal contribution (vertical bars) to immunophenotypic BM haematopoietic populations in 662 
patient samples pre-ENA and at CR (horizontal bars).  Data is from SCG except for mature 663 
GM population pre-ENA, where the flow-sorted cell population was genotyped (*).  664 
e) Clonal contribution to colonies grown from CR sample (percentage of genotyped, 665 
individually picked colonies) as in Fig. 3e. 666 
f) Lineage affiliation of colonies from BM CD34+ cells purified from CR sample compared 667 
with normal CB (as in Fig. 2e).  668 
Figure 5. Mechanisms leading to relapse of enasidenib-treated patients.  669 
a) Summary of mechanisms (rows) leading to relapse in 12 patients (columns). Selected 670 
mutations detected at relapse by WES (all patients except #104-021) or by Heme Panel bait 671 
capture sequencing (#104-021) are shown.  672 
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b) Longitudinal analysis of the percentage suppression of serum 2-HG concentrations prior 673 
to enasidenib treatment (pre-ENA), at best response (CR or PR) and at relapse in 14 674 
patients with an IDH2 R140 codon mutation.  675 
c-d) Serum 2-HG levels and bone marrow blast percentages prior to enasidenib treatment 676 
(pre-ENA), at CR or CRp (complete remission without platelet recovery) during the course of 677 
treatment (C=cycle, D=day of treatment) and at relapse in patients #201-014 (c) and #201-678 
022 (d).  679 
e-f) Serial mutation analyses in flow-sorted blasts prior to enasidenib treatment (pre-ENA) 680 
and at relapse in patients #201-014 (e) and #201-022 (f).  681 
Figure 6. Relapse post-enasidenib occurs through clonal evolution/selection.  682 
 683 
a) Patient #104-021: Heat map of targeted re-sequencing of mutations (rows) in single cells 684 
(n=214 cells, columns) from flow-sorted BM populations pre-treatment and at relapse which 685 
are shown together. The key is as in Fig. 3a.  686 
b) Clonal structure of patient #104-021 based on SCG. The key to the panel is as in Fig. 3b. 687 
Boxes in dotted red lines highlight clones which are only detected at relapse.  688 
c) Clonal composition in different immunophenotypic compartments pre-ENA and at relapse, 689 
as in Fig. 3c. 690 
d) Clonal contribution (vertical bars) to immunophenotypic BM haematopoietic populations in 691 
patient samples pre-ENA and at relapse (horizontal bars).  Data is from SCG.   692 
e) Patient #201-011: Heat map of targeted re-sequencing of mutations (rows) in single cells 693 
(n=87 cells, columns) from flow-sorted BM populations at relapse. The key is as in Fig. 3a.  694 
f) Clonal structure of patient #201-011 at relapse.  * indicates 6 cells with genotype “DIA” 695 
where we detected ADO in 4/5 cells in the DNMT3A allele. Ø denotes “DId”. The estimated 696 
ADO frequency of the ASXL1 allele was 12.1%. § indicates 6/7 “DIXF” cells where there was 697 
ADO for the DHX15 R222G mutant allele. See also Supplementary Fig. 12c. Boxes in dotted 698 
red lines as in (b). 699 
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g) Clonal composition in different immunophenotypic compartments at relapse, as in Fig. 3c. 700 
h) Clonal contribution (vertical bars) to immunophenotypic BM haematopoietic populations in 701 
patient samples at relapse (horizontal bars).  Data is from SCG.   702 
Online Materials and Methods  703 
Please see also the Life Sciences Reporting Summary 704 
Patient samples 705 
Bone marrow (BM) or blood samples from normal donors and AML patients were obtained 706 
with informed consent and collected by research ethics committee-approved Biobanks 707 
(MDSBio Study, MREC 06/Q1606/110, Oxford Musculoskeletal Biobank, MREC 708 
09/H0606/11: South Central Oxford C REC), Gustave Roussy (Department of Clinical 709 
Hematology and Drug Development Department (DITEP), Gustave Roussy, Villejuif) and 710 
MSKCC Biobanks. Cytogenetic analyses were performed in clinical laboratories. 711 
Mononuclear cells (MNCs) were isolated by Ficoll density gradient. MNCs were viably frozen 712 
in 90% FCS/10% DMSO in liquid nitrogen. 713 
Measurement and analysis of 2-hydroxyglutarate (2-HG) 714 
Serum samples were collected within 28 days before the first dose of enasidenib 715 
(‘screening’) and/or pre-dose on day 1 of each treatment cycle. 2-HG concentration was 716 
determined by liquid chromatography tandem mass spectrometry (Covance, Inc USA 717 
according to their validated method). Baseline 2-HG was either the average of the screening 718 
sample and pre-dose cycle 1 sample, or either sample if both were not available. Percentage 719 
suppression of 2-HG was determined by comparing the lowest level of 2-HG observed on-720 
treatment to baseline. 721 
Hematopoietic cell immunophenotyping 722 
Frozen BMMNCs from normal donors or AML samples were washed with Iscove’s Modified 723 
Dulbecco’s Medium (Thermo Fisher Scientific, UK), 10% fetal bovine serum (Sigma, UK) 724 
and 1mg/ml bovine pancreatic DNAse I (Sigma, UK). Cells were stained for flow cytometry 725 
with antibodies in Supplementary Table 8. Analysis was carried out on either BD LSR 726 
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Fortessa or BD FACSAria Fusion (Becton Dickinson, Oxford UK). Antibodies in the lineage 727 
(Lin) depletion are: anti-CD2,CD3,CD4,CD8a,CD10,CD19,CD20 and  CD235a. 7-728 
aminoactinomycin-D (7AAD, Becton Dickinson, UK) was used as a live/dead stain. 729 
Hematopoietic stem/progenitor cells were defined as subsets of Lin-CD34+ and myeloid 730 
precursor as Lin-CD34-CD117+ as previously described21. Terminally mature myeloid cells 731 
were defined as Lin-CD34-CD117-.  732 
Mutational analysis by FoundationOne® Heme Panel 733 
Analysis of samples in Fig. 1a by FoundationOne® Heme panel was conducted by 734 
Foundation Medicine, Inc. Nucleic acid libraries were prepared from DNA and RNA extracted 735 
from fresh patient BM samples and captured using custom bait-sets targeting 405 cancer-736 
related genes by DNA-sequencing (DNA-seq), and 265 frequently rearranged genes by 737 
RNA-sequencing (RNA-seq). Genes included in this analysis encode known or likely targets 738 
of therapies, either approved or in clinical trials, or are otherwise known drivers of 739 
oncogenesis published in the literature52. 740 
Mutational analysis by Fluidigm Access Array 741 
Selected samples from Fig. 1a and Supplementary Table 2 was performed using highly 742 
multiplexed PCR-based targeted re-sequencing with a custom panel of 373 amplicons 743 
covering areas of high frequency AML mutations in 35 genes, using the Fluidigm Access 744 
Array platform as previously described6. 745 
Mutational analysis by whole exome sequencing (WES). 746 
Genomic DNA from flow-sorted AML blasts or CD3-positive cells (germline control) was 747 
purified with Allprep DNA/RNA mini or micro Kits (Qiagen, France). After exome capture with 748 
SureSelect V5 Mb All Exon kit (Agilent, Les Ulis, France), paired-end 100 bp sequencing 749 
was performed on HiSeq2000 (Illumina, Paris France). Read alignment  to hg19 reference 750 
genome was performed using the BWA algorithm, v0.7.10 with corrections using GATK 751 
(v3.3.0) after removal of PCR duplicates.  Variant detection was carried out with VARSCAN 752 
(v2.3.7). Somatic variants (Supplementary Table 2) were selected using the following 753 
criteria: minimum depth: 8x, VAF>10% in AML blasts and lower than 10% in germline 754 
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control, and p-value <0.001. All variants were manually inspected using IGV (v2.3) software. 755 
Artifactual variants from DNA oxidation where read pair orientation bias was observed (i.e. 756 
predominant F2R1 orientation for C to A variations or F1R2 for G to T variations) were 757 
filtered out. Median depth at the positions reported in the Supplementary Table 2 was 121 758 
(range: 19-843). 759 
Selection of mutations for targeted re-sequencing in populations and single cells. 760 
On average 23 somatic mutations were detected per AML sample by WES. We selected 761 
mutations for further validation by targeted re-sequencing and SCG based on the following 762 
criteria: 1) known recurrent mutations in AML, 2) non-recurrent mutations in genes 763 
commonly mutated in AML.  In addition, mutations not meeting above criteria, but where the 764 
VAF varied by at least 5% between sequential samples in the same patient were of interest 765 
as these may be markers of clonal shifts.  Where multiple mutations had similar VAFs and 766 
showed similar patterns of change in VAFs in sequential samples, a representative mutation 767 
was selected. This is illustrated in the example from patient #201-011 (Supplementary 768 
Figure 11a).  Mutations which were not validated by targeted re-sequencing were excluded 769 
in subsequent data analysis.  Chromosomal loss of heterozygosity detected by WES (or by 770 
karyotyping) was examined using germline single nucleotide polymorphisms (SNP) present 771 
in the affected chromosomal region. 772 
Mutational analysis by targeted re-sequencing 773 
Mutations detected by targeted re-sequencing in hematopoietic cell populations are in 774 
Supplementary Table 3. Average and range of read depths for each mutation is shown in 775 
Supplementary Table 4. DNA was extracted (DNeasy Blood and Tissue extraction kit, 776 
#69506 Qiagen Manchester UK) from bulk and flow-sorted cells from patient samples. 777 
Where material was limiting, whole genome amplification (WGA, RepliG, Qiagen, UK)) was 778 
performed. Targeted PCR was performed using high Fidelity Phusion Taq polymerase (NEB, 779 
UK) or KAPA2G Multiplex DNA Polymerase (KAPA Biosystems, UK) with 10ng of gDNA. 780 
Primers used are in Supplementary Table 7. A second PCR reaction added Illumina 781 
barcodes and sequencing oligonucleotides prior to sample purification, quantitation, pooling 782 
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and library preparation for sequencing on Illumina MiSeq (Illumina, Saffron Walden, UK). 783 
Raw data (average depth ~996x) was aligned using Stampy (v1.0.20)53. A minimum 784 
sequencing depth of 100 was set as a threshold for inclusion of data for analysis. >94% of 785 
reads had Phred scores of >30. VAF was obtained using the Unix ‘grep’ (globally search 786 
regular expression and print) command line.  787 
Mutant IDH2 variant allele frequency by quantitative PCR.  788 
mIDH2 VAF was assessed in gDNA extracted from flow-sorted patient blood CD14+ 789 
monocytes, CD16+ neutrophils, or polymorphonuclear neutrophils  (Ficoll gradient 790 
purification) at various time points during enasidenib treatment. Quantitative SNP assay 791 
PCR (12.5ng DNA per test) was performed using TaqMan® Universal PCR Master Mix 792 
(Applied Biosystems, France), TaqMan® probes (specific for either IDH2 wild type (FAM) or 793 
mutated R140Q (VIC) alleles (rs121913502, Applied Biosystems, France)). PCR was 794 
performed on an ABI 7500 Fast Real-Time PCR analyzer (Applied Biosystems, France) with 795 
cycling conditions: initial 1min at 60°C, 10min at 95°C, followed by 40 cycles of 15sec at 796 
95°C and 1min at 60°C; and then 1min at 60°C. 797 
Single cell genotyping 798 
Mutations interrogated by SCG are in Supplementary Table 3. Single cells were flow-sorted 799 
into 96 well plates containing 2µl of phosphate buffered saline. WGA was carried out using 800 
Single Cell RepliG kit (Qiagen, Crawley UK). Briefly, following cell lysis, alkali denaturation 801 
and neutralisation, a master mix containing Phi29 polymerase, dNTPs and random 802 
oligonucleotide primers was added. WGA was carried out at 300C for 8 hours followed by 803 
heat inactivation. Diluted (1:20) amplified DNA was used in single or multiplex PCR using 804 
primers relevant to the sample and high Fidelity Phusion Taq polymerase (NEB, UK) or 805 
KAPA2G Multiplex DNA Polymerase (KAPA Biosystems, UK). Barcoding and sequencing 806 
oligonucleotides were added by PCR and sequencing performed on Illumina MiSeq 807 
(Illumina, Saffron Walden, UK). ~94% of reads had Phred scores of >30. A threshold of 50 808 
reads was set for analysis inclusion. VAF thresholds for determining detection of mutations 809 
were determined by genotyping 48 single cells derived from normal bone marrow, and set at 810 
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the 95% confidence level (mean ± 1.96 x standard error of mean (SEM); i.e. <5% chance of 811 
false positive, Supplementary Table 6). 812 
Imputation of clonal structures using bulk VAFs 813 
The most common method used to impute clonal structure is based on the assumption that 814 
the most abundant mutation resides in the earliest occurring ancestral clone.  This method 815 
may be applicable to samples with linear clonal structures but it may not be able to 816 
accurately resolve more complex or branching clonal structures.  Longitudinal bulk 817 
genotyping data may offer additional information, particularly where there is evidence of 818 
clonal selection or evolution. 819 
Putative clonal structure is first solved for each sample independently using bulk VAF data 820 
based on the rules below. In samples where there was no colony or single cell (SC) 821 
genotyping, longitudinal sampling (pre-ENA, best response and relapse) can provide 822 
additional information on the likely clonal structure of that patient.  In the absence of colony 823 
or SCG data, bulk VAFs were used to estimate the size of the most likely clones in samples.  824 
In samples where there is associated colony and/ or single cell (SC) genotyping, the clonal 825 
structure was re-drawn based on these data, which provide a higher confidence structure 826 
with some resolution of intermediate clones. Once this clonal structure is solved, bulk VAF 827 
was used to estimate the sizes of clones in samples. 828 
Sequence of acquisition of mutations can be imputed from bulk genotyping data, using VAF 829 
as an estimate of clonal contribution (Supplementary Fig. 11b). Mutations are first ranked 830 
according to VAF: in these examples, VA is highest, VD is lowest. 831 
Factors which may cause data error and bias include limited cell equivalent representation in 832 
extracted genomic DNA from small cell numbers, bias present in whole genome amplified 833 
material and PCR bias (including sequencing bias).  While we were unable to control for the 834 
first two factors, we could estimate standard error of our sequencing data.  We performed 835 
technical replicate genotyping of 19 unsorted BMMC populations and obtained the standard 836 
error of mean (SEM) from VAFs from each mutation.  In total, 142 standard error values 837 
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were obtained, and the average SEM was 1.9% (range 0.0-20.2%), with a 95% confidence 838 
interval upper limit of 2.47%.  This limits our ability to reliably distinguish between clones 839 
varying in VAF of ~2.5% (~5% of cells if mutations were heterozygous), and we were not 840 
able to impute sequence of acquisition of mutations in population genotyping with less than 841 
2.5% difference in VAF between them.  Where three or four mutations have VAF within 2.5% 842 
of each other, the average VAF of the cluster is taken as the VAF of all mutations in that 843 
cluster (Supplementary Fig.11c).   844 
Interpreting VAFs and cellular representation in the context of loss of heterozygosity 845 
or hemizygosity. 846 
We detected multiple occurrences of loss of heterozygosity (LoH, e.g. copy-loss 847 
chromosomal deletions or copy-neutral uniparental disomy) and mutations, which were on 848 
the X chromosome in male patients (hemizygosity).  There is complexity in interpreting bulk 849 
VAFs due potential mix of cells with or without LoH within a bulk population.  850 
Notwithstanding this caveat, we used the simple models set out below to help interpret VAFs 851 
in different contexts.  For somatic heterozygous variants (somatic mutation or germline 852 
polymorphism) in autosomal chromosomes the estimated percentage cellular representation 853 
is 2xVAF% (Supplementary Fig. 11d).  Heterozygous variant and chromosomal deletion 854 
resulting in copy-loss LoH in autosomal chromosomes is illustrated in Supplementary Fig. 855 
11e.  Here, there is a non-linear relationship between VAF and cellular representation 856 
(Supplementary Fig. 11f).  The formula we used to estimate cellular representation was: % 857 
cellular representation= [-2.777 x (VAF ratio)2]+ (6.145 x VAF ratio) – 2.373.  In 858 
heterozygous variants and copy-neutral LoH (e.g. uniparental disomy) in autosomal 859 
chromosomes, percentage cellular representation is 100% -(2xVAF%) (Supplementary Fig. 860 
11g).  In X-linked variants in male subjects in sex chromosomes: percentage cellular 861 
presentation is the same as the VAF% (Supplementary Fig. 11h). 862 
Determination of clonal structures using single cell genotyping 863 
Each single cell was assessed for detection or non-detection of mutations in that patient 864 
sample by amplicon sequencing of DNA subject to whole genome amplification. A minimum 865 
 33
coverage of 30x across an amplicons was required for a amplicon to be called. We assigned 866 
the most likely sequence of acquisition of mutations based on the genotype identified in 867 
cells. For example, where mutations A, B, C, D and E were identified in a sample, discrete 868 
cells with genotypes A, AB, ABC, ABD, ABCD and AE may be called. In most cases the 869 
sequence of acquisition, e.g. A->AB, is clear. However, the sequence of acquisition of 870 
mutations during the transition for example, from AB to ABCD may not be clear due to allelic 871 
drop out (ADO) i.e. the sequence of acquisition may be AB -> ABC -> ABCD or AB-> ABD-> 872 
ABCD. In such cases, intermediate genotypes represented by most cells may be more likely 873 
to be true. In all cases, models of clonal structures which require the least number of 874 
discrete mutational steps required are represented54, although alternative structures, 875 
including ones where the same mutation is acquired twice, are possible. Once the most 876 
likely clonal structure is established, cells where there was failure to amplify a locus that did 877 
not alter the assignment of a mutational complement (e.g. an early mutation in the hierarchy) 878 
were included in the final analysis. 879 
Allele Drop Out Estimation (ADO) 880 
ADO can be measured for by two methods. First, ADO can be determined by determining 881 
the phase of germline SNPs near mutations. For patients #201-023 and #201-011, we 882 
genotyped germline SNPs which were either in-phase (i.e. on the same allele as) with a 883 
mutation or out of phase (i.e. on the opposite allele).  884 
In-phase SNPs were rs6597996 and rs11246258, DEAF1 N372K mutation, patient #201-885 
011. Out-of-phase SNPs were: (i) rs4911231, ASXL1 G646fs mutation, patient #201-023; (ii) 886 
rs2276598, DNMT3A R598X, patient #201-011; (iii) rs7657364, DHX15 R222G, patient 887 
#201-011. The SNPs were situated between 157 bases and 4 kilobases from the mutations. 888 
The threshold VAF for ascertaining dropout in these SNPs was <2% (homozygous 889 
reference) or >98% (homozygous variant).  890 
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In patient #201-023 (Fig. 3a-b) in 2/3 cells with the “AS” genotype there was ADO of one of 891 
the IDH2 alleles (Supplementary Fig. 12a, left) and in 2/12 cells with the genotype “SI” there 892 
was ADO in the ASXL1 allele (Supplementary Fig. 12a, right).  893 
Our analysis also showed that in patient #201-011 DNMT3A R598X and R736C mutations 894 
are on different alleles and the R736C mutation is in phase with rs2276598 (Supplementary 895 
Fig. 12b). 896 
By studying both VAFs of the SNP rs2276598 and the R736C mutation in cells with 897 
genotype “DIA” in patient #201-011 where ADO may have occurred we determined that in 898 
6/7 cells at CR, ADO of the allele that harboured the R598X mutation had occurred 899 
(Supplementary Fig. 12c left). Where the SNP did not amplify, the VAF of R736C mutation 900 
was informative. Similarly, in the same patient at relapse, 5/6 “DIA” cells at relapse had ADO 901 
of the R598X allele (Supplementary Fig. 12c center).  We also determined that in 6/7 cells 902 
with the “DIXF” genotype at relapse there had been ADO of the allele harbouring the DHX15 903 
R222G mutation (Supplementary Fig. 12c, right).  904 
An alternate method to determine ADO more globally is to study the frequency with which a 905 
variant is called homozygous (either reference or alternative) when it should be 906 
heterozygote. We analysed 6 SNPs in 5 genes (ASXL1, IDH2, DNMT3A, DEAF1 and 907 
DHX15) in 402 single cells from 2 patients (#201-011 and #201-023) known to be 908 
heterozygous in the germline (confirmed by genotyping population of flow sorted T cells from 909 
the patients). Mean VAF was 49.1% for all 6 SNPs with a near-symmetrical distribution of 910 
VAFs across these single cells ranging from 0-100% (Supplementary Fig. 12d). Frequencies 911 
of homozygous reference (VAF≤1%) or variant calls in the 402 cells (VAF≥99%, thresholds 912 
based on analysis of known homozygous SNPs in 237 cells) were 15.9% (64 cells/402 cells) 913 
and 15.2% (61 cells/402 cells) respectively (Supplementary Fig. 12d). 914 
Next, if we assume that mutations in patients were heterozygous (i.e. in cases where there is 915 
was no data to support uniparental disomy or copy number loss) we asked what was the 916 
frequency with which mutations were called homozygous (VAF≥99%) (presumably due to 917 
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ADO). Across the 23 mutations assessed using this method, the average ADO rate of wild 918 
type allele was 10.36% (SD 5.7%, Supplementary Fig. 12e). However, we found variation in 919 
ADO rates between different patients, even at the same mutation (e.g. IDH2 R172K), 920 
suggesting that ADO is affected by factors additional to that of the activity of the Phi21 921 
polymerase. Where possible we have used gene-specific germline SNPs, or alternatively 922 
used sample and mutation specific ADO estimated by the ‘homozygous mutant’ method for 923 
our analyses.  924 
Digital Droplet PCR 925 
We confirmed the VAFs detected by next-generation sequencing (NGS) using digital droplet 926 
PCR (ddPCR) in 17 amplicons and 113 sorted multi-cell AML populations from 5 patients 927 
using the BIORAD platform as previously described21. There was good correlation between 928 
VAF values obtained using these two methods (R2= 0.974,). There was one AML variant 929 
(DHX15 R222G) where NGS gave an unexpectedly high VAF in single normal BM MNCs 930 
(where the mutation was found to be absent in the bulk normal BM sample). Detection of this 931 
variant in normal and AML were therefore carried out using ddPCR which showed presence 932 
of the mutation in AML bulk and single cells, but confirmed its absence in normal bulk and 933 
single cells. 934 
Whole transcriptome sequencing (RNAseq) and analysis of alternative splicing events 935 
Copy DNA libraries were prepared using extracted RNA from AML blast cells flow-sorted 936 
from re- and post-relapse samples from patients #201-011 and #201-013. cDNA libraries 937 
were prepared for sequencing with tagmentation and indexing using Illumina Nextera 938 
Sample Preparation kit (Illumina, Saffron Walden, UK).  RNA-seq data were generated as 75 939 
bp paired-end unstranded Illumina reads. Reads were aligned using STAR(v2.4.0.1)55 to the 940 
human genome (GRCh37) with default parameters. On average alignment was 96.7% 941 
(range: 95.5-97.4%) with an average of 139x106 (range: 116x106-169x106) mapped reads 942 
per sample. Differentially spliced events (DSEs) for the wild type (pre-relapse) and post-943 
relapse with spliceosome gene mutations analysed as paired samples, were identified56 944 
using Mixture of Isoforms (MISO v0.5.4) using default parameters. An event is termed as 945 
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differentially spliced if the Bayes Factor (BF) ≥ 10, |∆ | > 0.2 where PSI is ‘percentage 946 
spliced in’, and the event is supported by ≥ 10 reads. DSEs are classified included or 947 
skipped spliced exons (SE), alternative 3’/5’ splice sites (A3SS, A5SS), mutually exclusive 948 
exons (MXE) or retained introns (RI). 949 
Colony assays  950 
25-250 cells were plated in duplicate in 1.2ml of MethoCult GFH4435 (StemCell 951 
Technologies, Manchester, UK).  AML patient samples were assayed with added Enasidenib 952 
(1µM). The rest of the procedure was as previously described20. 953 
Statistical Analysis 954 
Where applicable, statistical analyses were performed using with GraphPad Prism software 955 
(v7.02) using statistical methods noted in figure and table legends.  956 
 957 
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